5-<3(5)-pyrazolyl>oxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-<3(5)-pyrazolyl>oxazole
• 英文别名: 5-(1H-Pyrazol-3-yl)oxazole；5-(1H-pyrazol-5-yl)-1,3-oxazole
• 化学式: C₆H₅N₃O
• 分子量: 135.125
• InChiKey: ZJUCPZUEOHPCMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  对甲基苯磺酰甲基异腈 、 1H-吡唑-3-甲醛 在 potassium carbonate 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以44%的产率得到5-<3(5)-pyrazolyl>oxazole
  参考文献：
  名称：

  Saikachi, Haruo; Kitagawa, Tokujiro; Sasaki, Hideaki, Chemical and pharmaceutical bulletin, 1982, vol. 30, # 11, p. 4199 - 4204

  摘要：

  DOI：

文献信息

• Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
  申请人：——

  公开号：US20040176400A1

  公开（公告）日：2004-09-09

  The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof wherein the variables are as defined in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF). 1

  本发明提供了公式（I）的化合物，包括立体异构体、前药和其药学上可接受的盐或溶剂，其中变量如描述中所定义，以及其制备过程、含有它们的制药组合物以及它们在治疗由促肾上腺皮质激素释放因子（CRF）介导的疾病方面的用途。
• FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF)
  申请人：GLAXO GROUP LIMITED

  公开号：EP1383747A1

  公开（公告）日：2004-01-28
• ORGANIC LIGHT-EMITTING DIODE MATERIALS
  申请人：President and Fellows of Harvard College

  公开号：US20170244049A1

  公开（公告）日：2017-08-24

  Described herein are molecules for use in organic light emitting diodes. Example molecules comprise at least one acceptor moiety A, at least one donor moiety D, and optionally one or more bridge moieties B. Each moiety A is covalently attached to either the moiety B or the moiety D, each moiety D is covalently attached to either the moiety B or the moiety A, and each moiety B is covalently attached to at least one moiety A and at least one moiety D. Values and preferred values of moieties A, D, and B are defined herein.
• US7279474B2
  申请人：——

  公开号：US7279474B2

  公开（公告）日：2007-10-09
• [EN] FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF)<br/>[FR] PYRIMIDINES FONDUES UTILISEES EN TANT QU'ANTAGONISTES DE LA CORTICOLIBERINE (CRF)
  申请人：GLAXO GROUP LTD

  公开号：WO2002088095A1

  公开（公告）日：2002-11-07

  The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof wherein the variables are as defined in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).